As you will be aware, the Department of Health has asked NICE to conduct a Single Technology Appraisal of pertuzumab for untreated metastatic HER2-positive gastric or gastro-oesophageal junction cancer.
However, the company have advised that they will not be pursuing a licensing application for pertuzumab from the European Medicines Authority for this indication at this time. This decision is based on the results from the JACOB study, which did not meet its primary endpoint. Therefore, NICE has decided to suspend this appraisal on its work programme.
As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes